Post recategorizations of schemes, most erstwhile Multi Cap Schemes were converted to Flexi Cap schemes where Fund Managers can decide what Allocation to which Market cap bias.
Thanks to that, there are very few Multi Caps available now which allocates min 25% each to Large, Mid and Small Caps and balance 25% that can be at the discretion of the Fund Manager.
What is the benefit of Multi Caps?
1. It takes away Fund Manager bias of going overweight or underweight in any market Cap bias
2. Most Flexi Caps are overweight on Large Caps
3. Though not negatively correlated, Large caps perform well in Risk-off situations and when markets become over valued and Mid and small Caps generally outperform in Risk-on situations and can hugely outperform Large caps (like 2020 -2021). Drawdowns can be equally accentuated
4. Multi Cap category will surely not be part of many portfolios post conversion by most AMCs of existing Multi Caps to Flexi Cap schemes
5. An ideal category to invest to participate in all Market cap bias spaces
Finally an NFO to truly fill the void created post #SEBI recategorization of schemes.
I have always believed that NFOs should not be old wine in new bottle. It should fill void of a NEED of Investors or fill a void in an asset class which is not currently available.
I think Kotak Multi Cap NFO fills that NEED and the VOID both.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Many have asked me about spate of IPOs and NFOs launches and my thoughts. Should they invest or not?
Another question: why are AMCs launching NFOs at expensive valuations?
My thoughts on this subject:
If you had bought 5kg of sugar from a grocer & you order another 2kgs next day, will the grocer not sell you more? They are in the business of selling you day to day groceries.
What and how much you need is your choice as a customer. You cannot blame the grocer for selling
Put differently:
Which medicine(scheme) needed for which patient(Investor) is job of a Doctor(MFD) or patient(DIY Investor). It is not job of Pharma Companies(AMCs).
Just because Pharma Cos repackage the medicines, does not mean patients should increase their dose
Investors have short memories and wish to dissect market phases based on what suits their sensibilities.
Current hot topic of discussions on Social Media:
How Mid and Small Caps have delivered stupendous returns since March 2020
What they have conveniently forgotten is their recent past experience of investing in Mid & Small Caps from Jan 18 to Dec 19 and till Mar 20
Above table shows entire journey of same Indices over different time periods vs 2 popular DAAF schemes and vs Smart Solution of MisterBond
Many have questioned our exit from Equity in July 2020(after entries in March 2020):
As @morganhousel has mentioned in his book:
It is not being conservative but creating Margin of Safety. This raises odds of success at a given level of risk by raising your chance of survival
MisterBond's Rankings as on May 30'2021: From 01-04-15 to 30-05-21
Rankings of only those which were in existence from 01-04-15
Those wishing to subscribe can make an advance payment. Subscription will open from June 15 after making balance payment: misterbond.in/pricing.php
3 Types of Rankings: 1) IHR: Investor High Returns - Higher returns in higher return bands 2) IER: Investor Experience Returns - IHR adjusted for Volatility 3) % of observations of each scheme beating Industry Average
Large Cap Scheme Rankings:
Industry Avg: 8.50%
Number of Observations Completing 5 years: 284
Based on 5 year rolling returns